Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation

Alexandru V. Olaru, Florin M. Selaru, Yuriko Mori, Christine Vazquez, Stefan David, Bogdan Paun, Yulan Cheng, Zhe Jin, Jian Yang, Rachana Agarwal, John M. Abraham, Themistocles Dassopoulos, Mary Harris, Theodore M. Bayless, John Kwon, Noam Harpaz, Ferenc Livak, Stephen J. Meltzer

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Background: Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer. Aberrant microRNA (miR) expression has been linked to carcinogenesis; however, no reports document a relationship between IBD-related neoplasia (IBDN) and altered miR expression. In the current study we sought to identify specific miR dysregulation along the normal-inflammation-cancer axis. Methods: miR microarrays and quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) were used to detect dysregulated miRs. Receiver operating characteristic curve analysis was employed to test for potential usefulness of miR-31 as a disease marker of IBDNs. In silico prediction analysis, Western blot, and luciferase activity measurement were employed for target identification. Results: Several dysregulated miRs were identified between chronically inflamed mucosae and dysplasia arising in IBD. MiR-31 expression increases in a stepwise fashion during progression from normal to IBD to IBDN and accurately discriminated IBDNs from normal or chronically inflamed tissues in IBD patients. Finally, we identified factor inhibiting hypoxia inducible factor 1 as a direct target of miR-31. Conclusions: Our study reveals specific miR dysregulation as chronic inflammation progresses to dysplasia. MiR-31 expression levels increase with disease progression and accurately discriminates between distinct pathological entities that coexist in IBD patients. The novel effect of miR-31 on regulating factor inhibiting hypoxia inducible factor 1 expression provides a new insight on the pathogenesis of IBDN.

Original languageEnglish (US)
Pages (from-to)221-231
Number of pages11
JournalInflammatory Bowel Diseases
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

MicroRNAs
Inflammatory Bowel Diseases
Hypoxia-Inducible Factor 1
Neoplasms
Inflammation
Luciferases
Reverse Transcriptase Polymerase Chain Reaction
ROC Curve
Computer Simulation
Disease Progression
Colorectal Neoplasms
Carcinogenesis
Mucous Membrane
Western Blotting

Keywords

  • factor inhibiting hypoxia inducible factor 1
  • IBD-related neoplasia
  • inflammatory bowel disease
  • microRNA

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Olaru, A. V., Selaru, F. M., Mori, Y., Vazquez, C., David, S., Paun, B., ... Meltzer, S. J. (2011). Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflammatory Bowel Diseases, 17(1), 221-231. https://doi.org/10.1002/ibd.21359

Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. / Olaru, Alexandru V.; Selaru, Florin M.; Mori, Yuriko; Vazquez, Christine; David, Stefan; Paun, Bogdan; Cheng, Yulan; Jin, Zhe; Yang, Jian; Agarwal, Rachana; Abraham, John M.; Dassopoulos, Themistocles; Harris, Mary; Bayless, Theodore M.; Kwon, John; Harpaz, Noam; Livak, Ferenc; Meltzer, Stephen J.

In: Inflammatory Bowel Diseases, Vol. 17, No. 1, 01.01.2011, p. 221-231.

Research output: Contribution to journalArticle

Olaru, AV, Selaru, FM, Mori, Y, Vazquez, C, David, S, Paun, B, Cheng, Y, Jin, Z, Yang, J, Agarwal, R, Abraham, JM, Dassopoulos, T, Harris, M, Bayless, TM, Kwon, J, Harpaz, N, Livak, F & Meltzer, SJ 2011, 'Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation', Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 221-231. https://doi.org/10.1002/ibd.21359
Olaru, Alexandru V. ; Selaru, Florin M. ; Mori, Yuriko ; Vazquez, Christine ; David, Stefan ; Paun, Bogdan ; Cheng, Yulan ; Jin, Zhe ; Yang, Jian ; Agarwal, Rachana ; Abraham, John M. ; Dassopoulos, Themistocles ; Harris, Mary ; Bayless, Theodore M. ; Kwon, John ; Harpaz, Noam ; Livak, Ferenc ; Meltzer, Stephen J. / Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. In: Inflammatory Bowel Diseases. 2011 ; Vol. 17, No. 1. pp. 221-231.
@article{7811772baeef494a9bf611826a694065,
title = "Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation",
abstract = "Background: Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer. Aberrant microRNA (miR) expression has been linked to carcinogenesis; however, no reports document a relationship between IBD-related neoplasia (IBDN) and altered miR expression. In the current study we sought to identify specific miR dysregulation along the normal-inflammation-cancer axis. Methods: miR microarrays and quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) were used to detect dysregulated miRs. Receiver operating characteristic curve analysis was employed to test for potential usefulness of miR-31 as a disease marker of IBDNs. In silico prediction analysis, Western blot, and luciferase activity measurement were employed for target identification. Results: Several dysregulated miRs were identified between chronically inflamed mucosae and dysplasia arising in IBD. MiR-31 expression increases in a stepwise fashion during progression from normal to IBD to IBDN and accurately discriminated IBDNs from normal or chronically inflamed tissues in IBD patients. Finally, we identified factor inhibiting hypoxia inducible factor 1 as a direct target of miR-31. Conclusions: Our study reveals specific miR dysregulation as chronic inflammation progresses to dysplasia. MiR-31 expression levels increase with disease progression and accurately discriminates between distinct pathological entities that coexist in IBD patients. The novel effect of miR-31 on regulating factor inhibiting hypoxia inducible factor 1 expression provides a new insight on the pathogenesis of IBDN.",
keywords = "factor inhibiting hypoxia inducible factor 1, IBD-related neoplasia, inflammatory bowel disease, microRNA",
author = "Olaru, {Alexandru V.} and Selaru, {Florin M.} and Yuriko Mori and Christine Vazquez and Stefan David and Bogdan Paun and Yulan Cheng and Zhe Jin and Jian Yang and Rachana Agarwal and Abraham, {John M.} and Themistocles Dassopoulos and Mary Harris and Bayless, {Theodore M.} and John Kwon and Noam Harpaz and Ferenc Livak and Meltzer, {Stephen J.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1002/ibd.21359",
language = "English (US)",
volume = "17",
pages = "221--231",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation

AU - Olaru, Alexandru V.

AU - Selaru, Florin M.

AU - Mori, Yuriko

AU - Vazquez, Christine

AU - David, Stefan

AU - Paun, Bogdan

AU - Cheng, Yulan

AU - Jin, Zhe

AU - Yang, Jian

AU - Agarwal, Rachana

AU - Abraham, John M.

AU - Dassopoulos, Themistocles

AU - Harris, Mary

AU - Bayless, Theodore M.

AU - Kwon, John

AU - Harpaz, Noam

AU - Livak, Ferenc

AU - Meltzer, Stephen J.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer. Aberrant microRNA (miR) expression has been linked to carcinogenesis; however, no reports document a relationship between IBD-related neoplasia (IBDN) and altered miR expression. In the current study we sought to identify specific miR dysregulation along the normal-inflammation-cancer axis. Methods: miR microarrays and quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) were used to detect dysregulated miRs. Receiver operating characteristic curve analysis was employed to test for potential usefulness of miR-31 as a disease marker of IBDNs. In silico prediction analysis, Western blot, and luciferase activity measurement were employed for target identification. Results: Several dysregulated miRs were identified between chronically inflamed mucosae and dysplasia arising in IBD. MiR-31 expression increases in a stepwise fashion during progression from normal to IBD to IBDN and accurately discriminated IBDNs from normal or chronically inflamed tissues in IBD patients. Finally, we identified factor inhibiting hypoxia inducible factor 1 as a direct target of miR-31. Conclusions: Our study reveals specific miR dysregulation as chronic inflammation progresses to dysplasia. MiR-31 expression levels increase with disease progression and accurately discriminates between distinct pathological entities that coexist in IBD patients. The novel effect of miR-31 on regulating factor inhibiting hypoxia inducible factor 1 expression provides a new insight on the pathogenesis of IBDN.

AB - Background: Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer. Aberrant microRNA (miR) expression has been linked to carcinogenesis; however, no reports document a relationship between IBD-related neoplasia (IBDN) and altered miR expression. In the current study we sought to identify specific miR dysregulation along the normal-inflammation-cancer axis. Methods: miR microarrays and quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) were used to detect dysregulated miRs. Receiver operating characteristic curve analysis was employed to test for potential usefulness of miR-31 as a disease marker of IBDNs. In silico prediction analysis, Western blot, and luciferase activity measurement were employed for target identification. Results: Several dysregulated miRs were identified between chronically inflamed mucosae and dysplasia arising in IBD. MiR-31 expression increases in a stepwise fashion during progression from normal to IBD to IBDN and accurately discriminated IBDNs from normal or chronically inflamed tissues in IBD patients. Finally, we identified factor inhibiting hypoxia inducible factor 1 as a direct target of miR-31. Conclusions: Our study reveals specific miR dysregulation as chronic inflammation progresses to dysplasia. MiR-31 expression levels increase with disease progression and accurately discriminates between distinct pathological entities that coexist in IBD patients. The novel effect of miR-31 on regulating factor inhibiting hypoxia inducible factor 1 expression provides a new insight on the pathogenesis of IBDN.

KW - factor inhibiting hypoxia inducible factor 1

KW - IBD-related neoplasia

KW - inflammatory bowel disease

KW - microRNA

UR - http://www.scopus.com/inward/record.url?scp=78650108135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650108135&partnerID=8YFLogxK

U2 - 10.1002/ibd.21359

DO - 10.1002/ibd.21359

M3 - Article

VL - 17

SP - 221

EP - 231

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -